Antibody therapeutics: A new era for EGFR-mutant NSCLC treatment.
New antibody-based drugs overcome resistance mechanisms that stop small-molecule therapies from working in lung cancer, extending treatment options post-progression.
This review summarizes the evolving landscape of antibody-based therapies for EGFR-mutant NSCLC, focusing on amivantamab, bispecific antibodies, and ADCs that overcome acquired TKI resistance mechanisms. The antibody therapeutics era represents a paradigm shift from small-molecule-only strategies and offers new options for post-osimertinib progression.
What the study was
- Study design
- Narrative review
- Population
- EGFR-mutant NSCLC patients with acquired resistance
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Biochimica et biophysica acta. Reviews on cancer
Why it surfaced
Timely review of antibody therapeutics redefining EGFR+ NSCLC management; covers amivantamab and emerging ADCs with near-term clinical implementation in a major cancer subtype.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.